- New exclusive distribution agreement for REXIM® amino acids strengthens Brenntag’s role in the Biopharma and API markets
- Brenntag assumes full responsibility for the market development and distribution across most of Europe since July 1
Brenntag, the global market leader in chemicals and ingredients distribution, announced today a new strategic partnership with Evonik REXIM® for the distribution of its GMP grade amino acids to the pharmaceutical and biopharmaceutical markets in Europe, effective July 1, 2026. The agreement covers most parts of Europe, including DACH region, UK, France, Benelux, Scandinavia, CEE, Israel, Turkey and more (excluding Italy, Ukraine, Middle East and Africa).
Amino acids are fundamental building blocks of life and essential components of proteins, driving key biochemical and metabolic processes. REXIM® provides highly purified natural and non‑natural amino acids and derivatives. Their quality and reliability make them suitable across multiple regulated applications - serving as essential ingredients in medical nutrition, pharmaceutical APIs and excipients, as well as consistent nutrients for cell culture media in biopharma.
Evonik REXIM is a leading supplier of highest quality amino acids and offers relevant parts of the production from domestic European supplies. The company combines market leadership in fermentation, bioconversion and synthetic-based manufacturing. The collaboration with Brenntag supports Evonik REXIM’s strategy, expanding its presence in key global markets and providing customers with enhanced local service, technical support, and long term supply security.
“Our collaboration with Evonik reflects Brenntag’s commitment to bringing high-value pharmaceutical ingredients and solutions closer to our customers,” says Joakim Rehné, President Brenntag Pharma EMEA. “By combining Evonik’s world-class expertise in GMP amino acids with Brenntag’s extensive market presence, technical capabilities, and regulatory know-how, we are uniquely positioned to support the evolving needs of pharmaceutical and biopharmaceutical manufacturers across the region. Together, we are creating a stronger, more reliable supply network that helps accelerate innovation and ensure patient access to critical therapies.”
“Our partnership with Brenntag significantly strengthens Evonik REXIM’s market reach,” says Thomas Hermann, Head of the REXIM® product line at Evonik Health Care. “Brenntag’s strong regional footprint, deep customer relationships, and extensive experience in the life-science sector make them an ideal partner. Together, we can provide customers with reliable access to high quality GMP amino acids and support the fast growing pharmaceutical and biopharmaceutical markets”.
About Evonik:
Evonik is a global chemical company, headquartered in Essen, Germany, active in more than 100 countries and generated sales of €14.1 billion and earnings (adjusted EBITDA) of €1.9 billion in 2025. Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The common motivation of the approximately 31,000 employees is to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day. For more on Evonik and the REXIM® product range visit: https://healthcare.evonik.com/en/biopharma/amino-acids/rexim-portfolio
